Literature DB >> 29126497

Radiation Therapy for Oral Cavity and Oropharyngeal Cancers.

Alexander Lin1.   

Abstract

Radiotherapy is a key therapeutic modality used in the treatment of oral cavity and oropharyngeal cancers, whether as definitive treatment or postoperatively for those with high-risk factors after surgery. Although radiotherapy is a proven, effective treatment of cancer control, it can result in significant acute and late toxicities. Pretreatment patient education, supportive care, and posttreatment adherence to rehabilitative and preventive care can help mitigate toxicities. Advances in radiation delivery, such as through continued technological advances, or novel approaches to customizing radiation dose and volume, to maximize the therapeutic efficacy while minimizing side effects, are warranted.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Head and neck cancer; Intensity-modulated radiation therapy; Oral cavity cancer; Oropharyngeal cancer; Radiation therapy

Mesh:

Year:  2017        PMID: 29126497     DOI: 10.1016/j.cden.2017.08.007

Source DB:  PubMed          Journal:  Dent Clin North Am        ISSN: 0011-8532


  8 in total

1.  Synergistic Antiproliferation of Cisplatin and Nitrated [6,6,6]Tricycle Derivative (SK2) for a Combined Treatment of Oral Cancer Cells.

Authors:  Sheng-Chieh Wang; Ching-Yu Yen; Jun-Ping Shiau; Meng-Yang Chang; Ming-Feng Hou; Jiiang-Huei Jeng; Jen-Yang Tang; Hsueh-Wei Chang
Journal:  Antioxidants (Basel)       Date:  2022-05-08

Review 2.  Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.

Authors:  Bo Yang; Tingjun Liu; Yang Qu; Hangbo Liu; Song Guo Zheng; Bin Cheng; Jianbo Sun
Journal:  Front Oncol       Date:  2018-11-28       Impact factor: 6.244

3.  Intraoperative Assessment of the Resection Specimen Facilitates Achievement of Adequate Margins in Oral Carcinoma.

Authors:  Roeland W H Smits; Cornelia G F van Lanschot; Yassine Aaboubout; Maria de Ridder; Vincent Noordhoek Hegt; Elisa M Barroso; Cees A Meeuwis; Aniel Sewnaik; Jose A Hardillo; Dominiek Monserez; Stijn Keereweer; Hetty Mast; Ivo Ten Hove; Tom C Bakker Schut; Robert J Baatenburg de Jong; Gerwin J Puppels; Senada Koljenović
Journal:  Front Oncol       Date:  2020-12-23       Impact factor: 6.244

Review 4.  Performance of Intraoperative Assessment of Resection Margins in Oral Cancer Surgery: A Review of Literature.

Authors:  Elisa M Barroso; Yassine Aaboubout; Lisette C van der Sar; Hetty Mast; Aniel Sewnaik; Jose A Hardillo; Ivo Ten Hove; Maria R Nunes Soares; Lars Ottevanger; Tom C Bakker Schut; Gerwin J Puppels; Senada Koljenović
Journal:  Front Oncol       Date:  2021-03-30       Impact factor: 6.244

5.  Oxidative Stress-Dependent Synergistic Antiproliferation, Apoptosis, and DNA Damage of Ultraviolet-C and Coral-Derived Sinularin Combined Treatment for Oral Cancer Cells.

Authors:  Sheng-Yao Peng; Jen-Yang Tang; Ruei-Nian Li; Hurng-Wern Huang; Chang-Yi Wu; Chien-Chih Chiu; Fang-Rong Chang; Hong-Wei Zhang; Yun-Jou Lee; Jyh-Horng Sheu; Hsueh-Wei Chang
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

Review 6.  Specimen-driven intraoperative assessment of resection margins should be standard of care for oral cancer patients.

Authors:  Yassine Aaboubout; Ivo Ten Hove; Roeland W H Smits; Jose A Hardillo; Gerwin J Puppels; Senada Koljenovic
Journal:  Oral Dis       Date:  2020-09-13       Impact factor: 3.511

7.  Spacers with boluses applied to various sites of oral squamous cell carcinoma: Technical note and retrospective case series.

Authors:  Kunio Yoshizawa; Shinichi Aoki; Kan Marino; Masaki Matsuda; Akinori Moroi; Koichiro Ueki
Journal:  Mol Clin Oncol       Date:  2021-07-13

8.  Combined Treatment with Cryptocaryone and Ultraviolet C Promotes Antiproliferation and Apoptosis of Oral Cancer Cells.

Authors:  Sheng-Chieh Wang; Hsun-Shuo Chang; Jen-Yang Tang; Ammad Ahmad Farooqi; Yun-Tzu Kuo; Yan-Der Hsuuw; Jai-Wei Lee; Hsueh-Wei Chang
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.